In today’s briefing:
- Healthvista India Pre-IPO Tearsheet
- Apollo Hospitals Enterprise (APHS IN): Set to Benefit from Medical Tourism Resumption in India
- BioMarin Pharmaceutical: Initiation of Coverage – Business Strategy, Key Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (07/22)
Healthvista India Pre-IPO Tearsheet
- Healthvista India (1370230D IN) is looking to raise about US$126m in its upcoming India IPO. The deal will be run by SBI Cap, IIFL Securities and JM Financial.
- Healthvista India is an out-of-hospital healthcare service provider. Under its brand Portea, it offers services such as primary care, geriatric and palliative care, amongst others.
- It also distributes specialty pharmaceuticals and provides “point of care” medical equipment for sale and rental.
Apollo Hospitals Enterprise (APHS IN): Set to Benefit from Medical Tourism Resumption in India
- Medical tourism in India was negatively impacted by the pandemic. As the government is lifting travel restrictions, reopening border, and resuming international flight services, medical tourists have started returning back.
- Large corporate hospitals, having pan-India presence, like Apollo Hospitals Enterprise (APHS IN) are set to benefit from this trend. Medical tourism contributed 10% of revenue of Apollo in pre-pandemic era.
- Apollo’s market dominance and expansion plan in hospital and foray into online services have sharpened its competitive edge over competitors. Its healthcare business is expected to grow mid-teens this year.
BioMarin Pharmaceutical: Initiation of Coverage – Business Strategy, Key Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (07/22)
- This is our first report on rare disease specialist, BioMarin Pharma.
- The company had a decent start to 2022 recording $519 million in total revenues in the previous quarter.
- The $20 million in Voxzogo contributions during the first quarter increased the company’s full-year 2022 guidance to between $100 million and $125 million and will play a significant role in its future growth.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars